

Asthma - Pipeline Review, H1 2020

https://marketpublishers.com/r/A85F4EF94C4EN.html Date: April 2020 Pages: 758 Price: US\$ 2,500.00 (Single User License) ID: A85F4EF94C4EN

Abstracts

Asthma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H1 2020, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma -Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in



therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 13, 46, 31, 6, 119, 29 and 9 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).

The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Asthma - Pipeline Review, H1 2020



Contents

- Introduction Asthma - Overview Asthma - Therapeutics Development Asthma - Therapeutics Assessment Asthma - Companies Involved in Therapeutics Development Asthma - Drug Profiles Asthma - Dormant Projects Asthma - Discontinued Products Asthma - Product Development Milestones
- Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Asthma, H1 2020 Number of Products under Development by Companies, H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020 Number of Products under Development by Universities/Institutes, H1 2020 Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020 Products under Development by Companies, H1 2020 Products under Development by Companies, H1 2020 (Contd..1), H1 2020 Products under Development by Companies, H1 2020 (Contd..2), H1 2020 Products under Development by Companies, H1 2020 (Contd..3), H1 2020 Products under Development by Companies, H1 2020 (Contd..4), H1 2020 Products under Development by Companies, H1 2020 (Contd..5), H1 2020 Products under Development by Companies, H1 2020 (Contd..6), H1 2020 Products under Development by Companies, H1 2020 (Contd..7), H1 2020 Products under Development by Companies, H1 2020 (Contd..8), H1 2020 Products under Development by Companies, H1 2020 (Contd..9), H1 2020 Products under Development by Companies, H1 2020 (Contd..10), H1 2020 Products under Development by Companies, H1 2020 (Contd..11), H1 2020 Products under Development by Companies, H1 2020 (Contd..12), H1 2020 Products under Development by Companies, H1 2020 (Contd..13), H1 2020 Products under Development by Companies, H1 2020 (Contd..14), H1 2020 Products under Development by Universities/Institutes, H1 2020 Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020 Number of Products by Stage and Target, H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020



Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020 Aumber of Products by Stage and Molecule Type, H1 2020 Asthma - Pipeline by 2A Pharma AB, H1 2020 Asthma - Pipeline by 3SBio Inc, H1 2020 Asthma - Pipeline by 4D Pharma PIc, H1 2020 Asthma - Pipeline by 4B Science SA, H1 2020

Asthma - Pipeline by AbbVie Inc, H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development for Asthma, H1 2020 Number of Products under Development by Companies, H1 2020 Number of Products under Development by Universities/Institutes, H1 2020 Number of Products by Top 10 Targets, H1 2020 Number of Products by Stage and Top 10 Targets, H1 2020 Number of Products by Top 10 Mechanism of Actions, H1 2020 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020 Number of Products by Top 10 Routes of Administration, H1 2020 Number of Products by Stage and Top 10 Routes of Administration, H1 2020 Number of Products by Top 10 Molecule Types, H1 2020 Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

2A Pharma AB 3SBio Inc 4D Pharma Plc **AB Science SA** AbbVie Inc Abeome Corp Adamis Pharmaceuticals Corp Adare Pharmaceuticals Inc Advagene Biopharma Co Ltd Aerami Therapeutics Akeso Biopharma Inc Algomedix Inc ALK-Abello AS Allergan Plc Amgen Inc Amphastar Pharmaceuticals Inc AnGes Inc Antisense Therapeutics Ltd Apollo Endosurgery Inc **Apollo Therapeutics LLC** Aquilon Pharmaceuticals SA



Argenx SE Artax Biopharma Inc Artizan Biosciences Inc **ASIT Biotech SA** Aslan Pharmaceuticals Ltd AstraZeneca Plc Atrapos Therapeutics LLC Aurigene Discovery Technologies Ltd AusBio Ltd Avidin Ltd Bai Shuo Beijing Pharmaceutical Technology Co Ltd Bilix Co Ltd Biocon Ltd **BiOraliX BV** BiosanaPharma BV **Biotec Pharmacon ASA** Boehringer Ingelheim International GmbH **Celltrion Inc** Celon Pharma SA Chia Tai Tianqing Pharmaceutical Group Co Ltd Chiesi Farmaceutici SpA Chronic Airway Therapeutics Ltd **ConMed Biosciences Inc Crossject SA** CrystalGenomics Inc CSL Ltd **CSPC** Pharmaceutical Group Ltd **Cumberland Pharmaceuticals Inc** Cynata Therapeutics Ltd Cytokinetics Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Co Ltd **Defensin Therapeutics ApS** Dnarx LLC EffectorBio Inc Eleusis Ltd EmphyCorp Inc **Energenesis Biomedical Co Ltd Enzychem Lifesciences Corp**



ethris GmbH **EURRUS Biotech GmbH Evelo Biosciences Inc** Exotect LLC F. Hoffmann-La Roche Ltd **Fibrotherapeutics Inc** Foresee Pharmaceuticals Co Ltd GeneFrontier Corp **Genentech Inc** Generium GeneScience Pharmaceuticals Co Ltd GlaxoSmithKline Plc **Glenmark Pharmaceuticals Ltd** GliaCure Inc **GlycoMira Therapeutics Inc Gossamer Bio Inc** Gurus BioPharm Harbour BioMed HEC Pharm Co Ltd Hoth Therapeutics Inc Hovione FarmaCiencia SA Humanigen Inc iCeutica Inc **Icure Pharmaceutical Inc IGE** Therapeutics Inc ILiAD Biotechnologies LLC Immune Regulation Ltd Inatherys InKemia IUCT Group SA Innovimmune Biotherapeutics Inc Inspyr Therapeutics Inc Invion Ltd **Ionis Pharmaceuticals Inc Irex Pharma LLC** JiangSu Qyuns Therapeutics Co Ltd JW Pharmaceutical Corp Kashiv BioSciences LLC **KBP BioSciences Co Ltd** Kissei Pharmaceutical Co Ltd



Kither Biotech Srl **KLUS Pharma Inc Knopp Biosciences LLC** KoBioLabs Inc Korea United Pharm Inc Kyowa Kirin Co Ltd Laboratorios LETI SL Lead Discovery Center GmbH LG Chem Ltd Lignamed LLC Longevity Biotech Inc Mabtech Ltd Mabwell Shanghai Bioscience Co Ltd Mariposa Health Ltd MD Healthcare Inc Medicenna Therapeutics Corp Mercia Pharma Inc Merck & Co Inc Mitsubishi Tanabe Pharma Corp Mycenax Biotech Inc NAL Pharmaceuticals Ltd NeoPharm Co Ltd Neovacs SA Novartis AG **OliX Pharmaceuticals Inc Omeros Corp** OncoArendi Therapeutics SA **Oncostellae SL Oneness Biotech Co Ltd Opsidio LLC Orbis Biosciences Inc** Orchid Pharma Ltd Orphomed Inc Oxagen Ltd Palo BioFarma SL Pantherics Inc Paradigm Biopharmaceuticals Ltd Paragen Bio Pty Ltd Pfizer Inc



PharmAbcine Inc

PharmaKing Co Ltd

Pharmaxis Ltd

Pieris Pharmaceuticals Inc

Progenra Inc

Prommune Inc

Prous Institute for Biomedical Research SA

Pulmatrix Inc

Pulmokine Inc

Qu Biologics Inc

Qurient Co Ltd

RAFT Pharmaceuticals

RAPT Therapeutics Inc

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Respiratorius AB

Revalesio Corp

ReveraGen BioPharma Inc

Ribomic Inc

S-TARget therapeutics GmbH

Saje Pharma LLC

Sama Pharm Co Ltd

Seelos Therapeutics, Inc.

Shanghai Kexin Biotech Co Ltd

Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co Ltd

Shouyao Holding Co Ltd

Siolta Therapeutics Inc

SolAeroMed Inc

sterna biologicals Gmbh & Co KG

Suzhou Connect Biopharmaceuticals Ltd

Swecure AB

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Tarus Therapeutics Inc

TCF GmbH

Tetragenetics Inc

Teva Pharmaceutical Industries Ltd

TFF Pharmaceuticals Inc



The Geneva Biotech Center SA Theravance Biopharma Inc **Torrent Pharmaceuticals Ltd Translational Biosciences** Trio Medicines Ltd **Tunitas Therapeutics Inc** United Biomedical Inc United BioPharma Inc Vactech Oy Vanworld Pharmaceutical (Rugao) Company Ltd Vascular BioSciences Vasomune Inc Vectura Group Plc Verona Pharma Plc Vicenna Pharmaceuticals Inc Yuhan Corp Zai Lab Ltd Zhejiang Hisun Borui Biopharmaceutical Co Ltd



I would like to order

Product name: Asthma - Pipeline Review, H1 2020

Product link: <u>https://marketpublishers.com/r/A85F4EF94C4EN.html</u>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A85F4EF94C4EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970